

DAFTAR PUSTAKA

1. Schaefer EJ, Santos RD. Xanthomatoses and lipoprotein disorders. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick's dermatology in general medicine. Edisi ke-8. New York: McGraw-Hill; 2012: p1600-1612.
2. Wulandari N, Nilasari H, Cipto H. Xantelasma, gambaran klinis dan penatalaksanaan. Media Dermato Venereologica Indonesia (MDVI). 2013; 40(1): p46-55.
3. Sharma P, Patgiri D, Sharma G, Pathak MS. Serum lipid profile in xanthelasma palpebrum. Indian Journal of Basic & Applied Medical Research. 2013;7(2): p732-737.
4. Dey A, Aggarwal R, Dwivedi S. Cardiovascular profile of xanthelasma palpebrarum. BioMed Research International; 2013: p1-3.
5. Greijmans E, Welkenhuyzen HL, Luijks H, Bovenschen HJ. Continuous wave potassium titanyl phosphate laser treatment is safe and effective for xanthelasma palpebrarum. American Society for Dermatologic Surgery. 2016(42): p860–866.
6. Nair PA, Singhai R. Xanthelasma palpebrarum-A brief review. Clinical, Cosmetic and Investigational Dermatology. 2018; 11: p1-5.
7. Bergman R, Friedman-Birnbaum R, Aviram M, Katz I, Kerner H, Brook J. Adult xanthogranulomatosis associated with abnormal apolipoprotein levels. Clin Exp Dermatol. 1990;15: p372-375.
8. Sharma SB, Dwivedi S, Prabhu KM, Kumar N, Baruah MC. Preliminary studies on serum lipids, apolipoprotein-b and oxidative stress in xanthelasma. Indian Journal of Clinical Biochemistry. 1999; 14(2): p245-248.
9. Laftah Z, Al-Niaimi F. Xanthelasma: An update on treatment modalities. Journal of Cutaneous and Aesthetic Surgery. 2018; 11(1): p1-6.
10. Zak A, Zeman M, Slaby A, Vecka M. Xanthomas: Clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014; 158(2): p181-188.

11. Jung SY, Hwang NH, Yoon ES, Park SH. Erbium: Yttrium aluminum garnet laser treatment for xanthelasma palpebrarum. *Medical Lasers; Engineering, Basic Research, and Clinical Application*. 2017; 6(1): p24-28.
12. Jonsson A, Sigfusson N. Significance of xanthelasma palpebrarum in the normal population. *Lancet*. 1976; p372-374.
13. Segal P, Insull W J, Chambless LE. The association of dyslipoproteinemia with corneal arcus and xanthelasma. *Circulation*. 1986; p1108-1118.
14. Roederer GO, Bouthillier O, Davignon J. Xanthelasma palpebrarum and corneal arcus in octogenarians. *N Engl J Med*. 1987; p1740.
15. Hidajat D, Hapsari Y, Hendrawan IW. Karakteristik penyakit kulit pada geriatri di Poliklinik kulit dan kelamin RSUD Provinsi Nusa Tenggara Barat periode 2012-2014. *Jurnal Kedokteran Universitas Mataram*. 2017,6(4): p7-13.
16. Zagoto YES, Lestari S, Asri E. Profile of xanthelasma during Januari 2014-December 2017 in Dermato-Venereology outpatient clinic of Dr. M. Djamil hospital Padang. *Regional Confrence of Dermatology*. 2018. Surabaya, Indonesia.
17. Aggarwal R, Rathore PK. A study evaluating xanthelasma palpebrarum clinically and biochemically. *International Journal of Contemporary Medical Research*. 2016; 3(9): p2565-2567.
18. Kavoussi. Serum lipid profile and clinical characteristics of patients with xanthelasma palpebrarum. *An Bras Dermatol*. 2016; p468-471.
19. Pandhi D, Gupta P, Singal A, Tondon A, Sharma SB, Madhu SV. Xanthelasma palpebrarum: A marker of premature atherosclerosis (risk of atherosclerosis in xanthelasma). *Postgrad Med J*; 2012; 88: p198-204.
20. Özdöl S, Sahin S, Tokgözoğlu L. Xanthelasma palpebrarum and its relation to atherosclerotic risk factors and lipoprotein (a). *The International Society of Dermatology International Journal of Dermatology*. 2008; 47: p785-789.

21. Dwivedi S, Aggarwal A, Singh S, Sharma V. Familial xanthelasma with Dyslipidemia: Just Another Family Trait?. *North American Journal of Medical Sciences*. 2012; 4: p238-240
22. Sarkany RPE, Breathnach SM, Seymour CA, Weismann K, Burns DA. Metabolic and nutritional disorders. Dalam: Burns T, Breathnach S, Cox N, Griffiths C, penyunting. *Rook's textbook of dermatology*. Edisi ke-7. Massachusetts: Blackwell Science; 2004: p57.66.
23. James WD, Berger TG, Elston DM. *Andrews's diseases of the skin clinical dermatology*. Edisi ke-9. Canada : Elsevier Incorporation, 2006. p532.
24. Jain A, Goyal P, Nigam PK, Gurbaksh H, Sharma RC. Xanthelasma palpebrarum: Clinical and biochemical profile in a tertiary care hospital of Delhi. *Indian Journal of Clinical Biochemistry*. 2007; 22(2): p151-153.
25. Caputo R, Monti M, Berti E. Normolipemic eruptive cutaneous xanthomatosis. *Arch Dermatol*. 1986; 122: p1294-1297.
26. Christoffersen M, Schmidt RF, Schnohr P, Jensen GB, Nordestgaard BG, Hansen AT. Xanthelasmata, arcus corneae, and ischaemic vascular disease and death in general population: prospective cohort study. *British Medical Journal*. 2011(343): p731-735
27. Arifah. *Peran lipoprotein dalam pengangkutan lemak tubuh*. 2006. Jakarta: EGC. p59-71
28. Santoso A. *PERKI. Pedoman tatalaksana dislipidemia*. 2013. Jakarta: Centra Communications. p5-27.
29. Turgeon RD, Anderson TJ, Gregoire J, Pearson GJ. 2016 Guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacist. *Canadian Journal Cardiology*. 2016; 32: p1263-1282.
30. Noël B. Premature atherosclerosis in patients with xanthelasma. *Journal of European Academy of Dermatology and Venereology*; 2007(21): p1244–1248.

31. Szalat R. Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy. *The Am Soc of Hem.* 2011: p3777-3783.
32. Bergman R. The pathogenesis and clinical significance of xanthelasma palpebrarum. *J Am Acad Dermatol.* 1994; 30: p236-42.
33. Cannon PS, Ajit R, Leatherbarrow B. Efficacy of trichloroacetic acid (95%) in the management of xanthelasma palpebrarum. *Clinical and Experimental Dermatology.* 2010; 35: p845–848.
34. Leonard JN, Dart JKG. The skin and the eyes. Dalam: Burns T, Breathnach S, Cox N, Griffiths C, penyunting. *Rook's textbook of dermatology.* Edisi ke-7. Massachusetts: Blackwell Science; 2004. p64.34.
35. Hirata Y, Okawa K, Ikeda M, Seike M, Matsumoto M, Kodama H. Low density lipoprotein oxidized in xanthoma tissue induces the formation and infiltration of foam cells. *J Dermatol Sci.* 2002; 30(3): p248-255.
36. Massengale WT, Nesbitt LTJ. Xanthomas. In: Callen JP, Salasche SJ, Stone MS, Horn TD, Schwarz T, Mancini AJ, Georg Stingl G, editors. *Bologna dermatology.* Edisi ke-2. New York: Mosby; 2008: p1411-1418.
37. Beny A. Perbedaan profil lipid pasien infark miokard akut dan non infark. Medan. Disertasi. 2010. p58-71.
38. Wang, H. Treatment of xanthelasma palpebrarum with intralesional pingyangmycin. *Dermatol Surg.* 2016;42: p368–376.
39. Rohrich RJ, Janis JE, Downell PH. Xanthelasma palpebrarum: A review and current management principles. *Plast Reconstr Surg.* 2002; 110: p1310-1314.
40. Haygood LJ, Bennett JD, Brodell RT. Treatment of xanthelasma palpebrarum with the bichloroacetic acid. *Dermatol Surg.* 1998; 24(9): p1027-1031.
41. Ghosh YK, Pradhan E, Ahluwalia HS. Excision of xanthelasma-clamp, shave and suture. *International Journal of Dermatology.* 2009; 48(2); p181-183.

42. Karsai S, Czarnecka A, Raulin C. Treatment of xanthelasma palpebrarum using a pulsed dye laser: A prospective clinical trial in 38 cases. *Dermatol Surg.* 2010; 2: p610-617.
43. Erwinanto. PERKI. Pedoman tatalaksana dislipidemia. 2013. P37-51.
44. Sniderman A, Couture P, Graaf Jd. *Nature Review. Endocrinology.* 2010; 6; p335–346.
45. Ana, Jonas. Lipoprotein structure. USA: Elsevier science. 2002. p32-39.
46. Comerford K, Andrew JLK. The beneficial effects on blood lipids and weight loss in healthy humans. *Obesity.* 2011: p1-7.
47. Artiss JD, Brogan K, Brucalc M, Moghaddame M, Jen KLC. The effects of a new soluble dietary fiber on weight gain and selected blood parameters in rats. *Metabolism Clinical and Experimental.* 2006; 55: p195–202.
48. Artiss JD, Jen KLC. Dietary fibers and body weight management: A brief review. *Journal of Clinical Ligand Assay.* 2005; 28(1): p1-4.
49. Jen KLC, George Grunberger, Artiss JD. On the binding ratio of α -cyclodextrin to dietary fat in humans. *Nutrition and Dietary Supplements.* 2013;5: p9–15.
50. Pietroleonardo L, Ruzicka T. Skin manifestasion in familial heterozygous hypercholesterolemia. *Acta Dermatoven.* 2009;18: p183-187.
51. Madiyono B, Moeslichan S, Sastroasmoro S, Budiman I, Purwanto SH. Perkiraan besar sampel. Dalam: Sastroasmoro S, Ismael S, eds. *Dasar-dasar metodologi penelitian klinis.* 5th ed. Jakarta: Sagung Seto; 2014: p376-377.
52. Walldius. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. *Lancet.* 2001;358(9298): p2026-2033.
53. Hughes S. Apolipoprotein B: A better measure of cardiac risk than LDL. 2003. p1-7
54. WHO. Monitoring Health for the Sustainable Development Goal. 2018. p35-37.

55. Shah AS, Wilson DP. Genetic disorders causing hypertriglyceridemia in children and adolescents. In: De Groot LJ, Chrousos G, Dugan K. South Dartmouth (MA): MDText.com.inc. 2016: p154-167.
56. Akyuz AR. Xanthelasma is associated with an increase amount of epicardial adipose tissue. *Med Princ Pract*. 2016; 25(2): p187-190.
57. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins and cardiovascular risk prediction. *Circulation* 2008;118:2047-56
58. Esmat. Risk of atherosclerosis in normolipidaemic patients with xanthelasma. *Clinical and Experimental Dermatology*. 2015(40);p373–378.
59. Setiawan HG, Kaligis SHM, Assa YA. Gambaran kadar apolipoprotein B (APO-B) serum pada vegetarian lacto-ovo. *Jurnal e-Biomedik (eBm)*. 2017(5);1: p1-4.

